Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Neflamapimod · VX-745, VD-31745

Small molecule · Inhibitor of mitogen-activated protein kinase 14 (p38α) (MAPK14) · developed by EIP Pharma

Phase 2 Most advanced trial
1 Registered trials

What is Neflamapimod?

Neflamapimod is a highly specific inhibitor of the intracellular enzyme mitogen-activated protein kinase 14 (p38α). It is being studied in nonfluent variant primary progressive aphasia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
VX-745, VD-31745, VRT-031745
Drug type
Small molecule
Targets
mitogen-activated protein kinase 14 (p38α) (MAPK14)
Mechanism
Inhibitor of mitogen-activated protein kinase 14 (p38α) (MAPK14)
Therapy area
Neurology
Developer
EIP Pharma Inc
In trials of
CRVO
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
TYL52QM320

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07033481 Phase 2 Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Active not recruiting CRVO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Nonfluent Variant Primary Progressive Aphasia (nfvPPA)

Other drugs acting on MAPK14

Sources

Updated Nov 8, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.